Nxstage Medical (NXTM) Reports In-Line Q4 EPS

Nxstage Medical (NASDAQ: NXTM) reported Q4 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $93 million versus the consensus estimate of $91.82 million.

Guidance

The Company is forecasting revenue to be between $400 and $405 million for the full fiscal year 2017, and between $95 and $97 million for the first quarter of 2017. The Company also expects to have positive net income for the full fiscal year 2017, and a net loss in the range of $1 to $3 million for the first quarter of 2017.

For earnings history and earnings-related data on Nxstage Medical (NXTM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c